The last month of summer saw several hires, including a lead for Worldwide Clinical Trials’ Japan operations, CEO appointments at CordenPharma and LabConnect, and Altasciences’ new CSO, who joins the company from Syneos.
908 Devices launches Rebel, a bioprocess analyzer, enabling researchers to conduct their own cell culture media analysis to accelerate process development ‘by weeks’.
NHS GDE Trust Worcestershire Health and Care collaborates with Clinithink to better manage its clinical data through the latter’s ‘natural language processing’ platform.
Researchers develop organ-on-an-electronic-chip platform to explore the electrophysiology of iPSC-derived cardiomyocytes and understand how the heart communicates.
Themis obtains an exclusive licence from Merck to develop vaccine candidates with an undisclosed indication, using its measles virus vector-based platform.
As summer heated up, the pharmaceutical industry saw major developments in preclinical models from new software to 3D-printed tissue, all in the name of drug development.
Researchers show miniature livers can develop steatohepatitis and fibrosis, pointing to potential for personalized hepatic drug discovery and toxicity platforms.
Schrödinger secures further funding, extends collaboration with Morphic Therapeutic on computational discovery platform for oral integrin drugs for the second time.
Engineered cardiac tissues generated using Tara Biosystems' heart-on-a-chip system predict how patients will respond to a range of drugs, as demonstrated in a recent study with GSK.
SGS’ OneVision initiative is working to standardize record-keeping across the global life sciences industry in an aim to accelerate laboratory testing, development, and eliminate paper-based systems.
Boehringer Ingelheim and the University of Texas MD Anderson Cancer Center entered a multi-year partnership to conduct collaborative translational research for lung and GI cancers.
Prellis advances its goal of using 3D holographic printing to create organoids for research and development – recently closing a $10.5m investment round to further develop its technology, which accelerates drug screening, says CEO.
Takeda and Sosei both have a proud heritage in Japan and recently entered a billion-dollar partnership with Sosei to discover, develop, and commercialize molecules for patients in need around the world.
Caprion Biosciences and HistoGeneX join forces, combining the two businesses to provide a source for immune monitoring, protein characterization, and tissue pathology solutions, as immunotherapy landscape evolves.
CordenPharma has a new CEO, Arbour Group advances plans to expand in RTP, Ashfield brings on a former Iqvia VP, and Recursion adds to its c-suite after raising $121m this month.
Aiming to speed up and facilitate the clinical development of liver failure treatments, Taconic launches the first commercially available diet-induced NASH rodent model.
Rosalind Franklin University of Medicine and Science opens its incubator, Helix 51, creating wet lab and research space for the Illinois bioscience hub.
A study by Biofourmis aims to improve patient centricity in the drug approval processes by using wearable technology and mobile software to monitor the quality of life for patients with heart failure.
A collaboration between Mercachem and Gotham leads to the generation of a molecule library, expected to enable new discovery opportunities in the epitranscriptomic targets space.
Lovelace’s support and the inclusion in a $20m NIH contract enable Exemplar to continue the development of a porcine animal model for Sickle Cell Disease research.
Novogene is working with Mission Bio to offer customers in China access to the Tapestri Platform, which is being used in the drug development process by LabCorp and more than a dozen institutions.
Recursion Pharmaceuticals plans to partner with big pharma on rare disease programs after raising $121m to build out its machine learning-enabled platform, which draws on an in-house developed dataset to support drug discovery and development.
The global drug discovery market is expected to reach $68bn in 2028, according to a Visiongain report, with revenue gains driven by flexibility, agility, and the ability to innovate, says Evotec executive.
Repositive ‘increases visibility’ while ‘maintaining confidentiality’ as it makes its directory of preclinical cancer models publicly browsable as part of the relaunch of its Cancer Models Platform.
StemoniX opens a new facility in California to house its research team working on its high-throughput microOrgan technology platforms for drug discovery and preclinical development.
Notocord, an Instem company, will provide data acquisition and analysis services to a research and innovation program to improve risk prediction of cardiovascular adverse events.
Boehringer Ingelheim, Sanofi, Bristol-Myers Squibb, and Evotec are among the top companies with “AI-friendly” CEOs, according to a report, which suggests that these businesses will prosper driven by a more effective application of AI.
Improving the prognostic value of early phase data is among one of several ways to increase the probability of successes in drug development, a process which has become more expensive as failure rates have risen, says an industry expert.
Lovelace Biomedical leads a collaboration with The Jackson Laboratory, Exemplar Genetics, Iontox, and the University of Pennsylvania as part of a $20m contract with the NIH.
Newly-minted Signant Health named a new CTO, Parexel bolstered its Japan presence, and BioAgilytix’s CEO was appointed to the board of FSD Pharma – a company developing products based on cannabinoids – among other people on the move in June.
WuXi Clinical is expanding therapeutically - investing ‘heavily’ in oncology, CNS, GI - and plans to continue growing geographically as well, with a mission to bridge the gap between China and the rest of the world.
A new 3D-printed, all-liquid device automates complex chemical reactions on demand – enabling drug screening with limited materials, such as patient biopsies, says researcher.
In which areas is artificial intelligence most mature? What are the challenges to widespread adoption? Tufts and DIA recently teamed up to explore these questions.
New this year to the discussion at DIA is the conversation around data ownership, as the industry continues to face a deluge of information from more sources than ever.
Zenith-Cognizant Technologies emerges from an acquisition aimed to streamline solutions as more complex “smart factories” become a greater focus in the biopharmaceutical industry.
Dassault Systèmes is set to acquire Medidata in an all-cash transaction valued at $5.8bn – a deal which will combine the power of modeling and simulation with data science to “catalyze the next generation of patient-inclusive therapeutics,” says CEO.
As the cell and gene therapies market evolves, CDMOs and pharmaceutical companies aim to adapt to the rising demands and serve larger patient populations.
Covance seeks an Economic Revitalization Area designation at its Indianapolis, IN-based site, at which the company looks to expand its sample storage capacity and add space “dedicated to innovation" as part of an $11.8m construction project.
